Seventh Statin Approved: Kowa Will Stress Livalo's Effect In Complex Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm says Livalo (pitavastatin) is only minimally metabolized by the liver through the CYP450 pathway, making the statin a better fit for patients treated for comorbid conditions.
You may also be interested in...
Novartis To Seek Licensing Partner For Pitavastatin
The firm is terminating development of its lipid-lowering agent pitavastatin after disappointing Phase II trial results.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.